1. Home
  2. MNY vs KLRS Comparison

MNY vs KLRS Comparison

Compare MNY & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MoneyHero Limited

MNY

MoneyHero Limited

HOLD

Current Price

$1.25

Market Cap

54.5M

Sector

N/A

ML Signal

HOLD

Logo Kalaris Therapeutics Inc.

KLRS

Kalaris Therapeutics Inc.

HOLD

Current Price

$8.41

Market Cap

46.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MNY
KLRS
Founded
2014
2019
Country
Singapore
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
54.5M
46.0M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
MNY
KLRS
Price
$1.25
$8.41
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
4
Target Price
$4.00
$20.67
AVG Volume (30 Days)
56.4K
157.6K
Earning Date
12-05-2025
02-24-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$69,182,746.00
N/A
Revenue This Year
$11.26
N/A
Revenue Next Year
$20.70
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.55
$2.14
52 Week High
$2.40
$12.90

Technical Indicators

Market Signals
Indicator
MNY
KLRS
Relative Strength Index (RSI) 44.63 55.13
Support Level $1.26 $8.26
Resistance Level $1.32 $9.09
Average True Range (ATR) 0.03 0.84
MACD -0.00 -0.19
Stochastic Oscillator 0.71 25.28

Price Performance

Historical Comparison
MNY
KLRS

About MNY MoneyHero Limited

MoneyHero Ltd is a personal finance aggregation and comparison company in Greater Southeast Asia. The firm is involved in the operation of online financial comparison platforms and related services for credit cards, personal loans, mortgages, insurance, and other financial products, connecting the providers of these products with well-matched and ready-to-transact consumers and generating revenue directly from these providers for placing their products on its platforms and providing insurance brokerage, marketing and events-related services. Geographically it operates in Singapore, Hong Kong, Taiwan, Malaysia and the Philippines.

About KLRS Kalaris Therapeutics Inc.

Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.

Share on Social Networks: